Detalhe da pesquisa
1.
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant.
Am J Transplant
; 2024 Apr 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38643944
2.
EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.
Pediatr Blood Cancer
; 67(3): e28126, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31850668
3.
Post-Transplant CD34+ Selected Stem Cell "Boost" for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies.
Biol Blood Marrow Transplant
; 24(7): 1527-1529, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29555312
4.
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Biol Blood Marrow Transplant
; 21(8): 1460-70, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25865646
5.
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Biol Blood Marrow Transplant
; 19(11): 1625-31, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24035782
6.
Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy.
Blood Adv
; 4(14): 3252-3257, 2020 07 28.
Artigo
Inglês
| MEDLINE | ID: mdl-32697816